(PDF) MS20.02 the Future of Stereotactic Ablative

MS20.02 the Future of Stereotactic Ablative Radiotherapy (SABR)

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.169

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

Imaging Follow-Up After Stereotactic Ablative Radiotherapy (SABR) for Lung Tumors

Journal of Radiation Oncology

Nuclear Medicine

English

Population-Based Phase II Trial of Stereotactic Ablative Radiotherapy (SABR) for Up to 5 Oligometastases: SABR-5

Cancer Research

English

MTE24.02 Small Lung Tumours: High Risk Lesions and Contraindications to Stereotactic Ablative Body Radiotherapy (SABR)

Journal of Thoracic Oncology

Respiratory Medicine

English

P2.16-15 Toxicities and Survival After Stereotactic Ablative Radiotherapy (SABR) for Centrally Located Lung Tumors

Journal of Thoracic Oncology

Respiratory Medicine

English

P3.08-17 Paediatric Motion Management Solutions for Particle Therapy Based Thoracic Stereotactic Ablative Body Radiotherapy (SABR)

Journal of Thoracic Oncology

Respiratory Medicine

English

Retrospective Analysis of Intrafraction Motion in Lung Stereotactic Ablative Body Radiotherapy (SABR) Patients at the Fraser Valley Centre

Journal of Medical Imaging and Radiation Sciences

Nuclear Medicine

Ultrasound Technology

English

Establishing a Histology-Specific Biologically Effective Dose Threshold for Lung Stereotactic Ablative Radiotherapy (SABR): Is ≥100 Gy10 Enough?

International Journal of Radiation Oncology Biology Physics

Cancer Research

Nuclear Medicine

English

Utilization of Stereotactic Ablative Radiotherapy in the Management of Oligometastatic Disease

Current Oncology

English

Are We Ready for Histology-Driven Stereotactic Ablative Radiotherapy?

Journal of Thoracic Oncology

Respiratory Medicine

English